Russo Partners’ Post

In established biotech markets such as the US, investment is distributed evenly across different stages of biotech ventures, as depicted in the graph below. To learn more about the stages in the lifecycle of biotech ventures, follow this link: https://lnkd.in/eeNpqdQb CC: Rakesh Gupta | Sumit Handa | Payal Jain | Neha A. | Kiran S | Bibek Singha | Aditya Vavilakolanu | Rishabh Nagori | Riya Sinha | Saish Patil | Udayan Nath #growth #investmentbanking #mergersandacquisitions #strategy #biotechnology #healthcare #fundraising #venturecapital

So far in 2024, at least 25 VCs have collectively raised $17.3 bn to fuel the biopharma industry! Highlights include: 🧬 Flagship Pioneering leading with $3.6 bn 🧪 Arch Venture Partners securing $3 bn for Fund XIII. 💊 Forbion’s €2.1 bn ($2.3 bn) close, including a record-setting €1.2 bn for their late-stage fund, making it the largest-ever European biopharma fund. This influx of capital is a significant boost for AI/ML, digital health, and late-stage growth equity investments. 🚀 For more details, check out the BioCentury Inc. article by Stephen Hansen & Matthew Krebs. 🌐 #Biotech #VentureCapital #Biopharma #Investment #DigitalHealth #Growth

Discover how biopharma venture capital is surging with $7.6B raised in Q2, signaling robust industry growth and a hotbed for investment, according to @jpmorgan. #BiopharmaGrowth #VentureCapital #IndustryTrends

VC Dollars Pour into Biopharma, with Q2 Haul Signaling Sunshine Ahead With venture investments pouring into biopharma, steady M&A deals and an increasingly widening IPO market, J.P. Morgan sees the industry returning to growth—finally. Venture dollars rose in the second quarter compared to the one prior, according to a new second-quarter licensing and venture report from the bank. BioPharma’s raised $7.6 billion in private financings across 107 investments, with the dollar value for both the second and first quarters beating the previous ones. The first quarter also saw 107 total rounds. The bank also suspects deal value will pick up in the second half as interest rates have plateaued and a rate cut is expected in September. J.P. Morgan is forecasting venture dollar volume to reach $28.2 billion by the end of the year, which would break a two-year downtrend. https://lnkd.in/gu9fuDNE #aspenalert #biotech #bioprocess

Looks like venBio has committed to another half a billion dollars to invest in biotechs working on diseases with unmet needs. The investments will be focused across all stages of clinical development but companies must provide beneficial data within 3-5 years. This suggests a good forward trend, however, risk management is still a heavier focus that comes with these investments. #VC #biotech #investments #riskmanagement

Regeneron, the 35-year-old drugmaker still led by its co-founders, is getting into the venture investing arena. The New York pharma will commit $100 million per year for five years, it said Monday morning. The drugmaker is the exclusive limited partner for the fund, which launched this month under the name Regeneron Ventures. It will invest in biotech startups, devices, tools and “enabling technologies.” Jay Markowitz #venturefunding #financing #pharma #pharmaceuticals #biotech #biotechnology #celltherapy #genetherapy #cellandgenetherapy #advancedtherapies #regenerativemedicine #startups #tools #technologies #devices #enablingtechnologies #lifesciences

Regeneron steps up! With the launch of Regeneron Ventures and a commitment of $100 million annually for five years, this landmark move can help revitalize the biotech startup ecosystem. The initiative could provide crucial support and open new opportunities for those affected by recent layoffs and shutdowns in the sector. Here's to empowering #entrepreneurs to bring innovative therapies from concept to patient care. #Biotech #VentureCapital #Innovation

M&A activity surges and IPOs return as the biotech industry navigates a changing business landscape marked by strategic consolidation and renewed investor focus on innovation. https://hubs.ly/Q02Lg7Dq0 #pharma #biotech #IPO #biospace

Epoch 37: Biotech Venture Capital Trends 👉Macro 👉Capital flows by therapeutic area 👉Capital flows by modality 👉Valuation Comps https://lnkd.in/dEkBy2bY

With venture investments pouring into biopharma, steady M&A deals and an increasingly widening IPO market, J.P. Morgan sees the industry returning to growth—finally. Venture dollars rose in the second quarter compared to the one prior, according to a new second-quarter licensing and venture report from the bank. Biopharmas raised $7.6 billion in private financings across 107 investments, with the dollar value for both the second and first quarters beating the previous ones. The first quarter also saw 107 total rounds.  “Venture investments returned with high-dollar rounds in Q2 to pour funds into biopharma and platform research, regardless of the company's clinical status. M&A activity maintained its healthy pace as the IPO market continued to open incrementally wider,” the report reads. #funding #financing #venturecapital #investment #ventureinvestment #growth #biopharma #biotech #biotechnology #pharma #pharmaceuticals #celltherapy #genetherapy #advancedtherapies #regenerativemedicine #lifescence #lifesciences #mergersandacquisitions #dealvalue #IPO #publicmarkets #brighterdays